Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Martin, Bigler"'
Autor:
Martin Zweifel, Beat Thürlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa
Publikováno v:
Endocrine Connections, Vol 6, Iss 7, Pp 549-556 (2017)
CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. The objective of this first-in man trial was to evalua
Externí odkaz:
https://doaj.org/article/c9dddec557f8412bb8c5901ee09bbf31
Autor:
Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study
Externí odkaz:
https://doaj.org/article/c9a8ea8a27db4f48921538bf341f9e66
Autor:
Beatrice Drexler, Jakob R. Passweg, Alexandar Tzankov, Martin Bigler, Alexandre PA Theocharides, Nathan Cantoni, Peter Keller, Georg Stussi, Axel Ruefer, Rudolf Benz, Geneviève Favre, Pontus Lundberg, Ronny Nienhold, Andrea Fuhrer, Christine Biaggi, Markus G. Manz, Mario Bargetzi, Simon Mendez-Ferrer, Radek C. Skoda
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tes
Externí odkaz:
https://doaj.org/article/8479aa021716446aad1f99447b3fef97
Autor:
S Farese, Urban Novak, J-M Luethi, Gabriela M. Baerlocher, Thomas Pabst, Martin Bigler, Beatrice U. Mueller, B Mansouri Taleghani, Katja Seipel, Axel Ruefer, Barbara Jeker, Daniel Betticher
Publikováno v:
Bone Marrow Transplantation. 53:175-179
Chemotherapy with G-CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing patients. Preclinical studies suggested that the nonsteroidal anti-inflammatory drug melox
Autor:
Nathan Cantoni, Axel Ruefer, Ronny Nienhold, Pontus Lundberg, Beatrice Drexler, Georg Stussi, Martin Bigler, Mario Bargetzi, Andrea Fuhrer, Radek C. Skoda, Jakob Passweg, Rudolf Benz, Markus G. Manz, Alexandre Theocharides, Alexandar Tzankov, Peter Keller, Geneviève Favre, Simón Méndez-Ferrer, Christine Biaggi
Publikováno v:
Haematologica
The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tes
Autor:
Susanne Bierbaum, Klaus W. Grätz, Martin Bigler, Bernd Stadlinger, Martin Rücker, Johanna Jauernik, Gregor J. Jenny
Publikováno v:
Journal of Biomedical Materials Research Part A. 104:2898-2910
This systematic review and meta-analysis evaluated the influence of biological implant surface coatings on periimplant bone formation in comparison to an uncoated titanium reference surface in experimental large animal models. The analysis was struct
Autor:
B. Thuerlimann, Christiane Pilop, Karin Rothgiesser, Peter Brauchli, Coya Tapia, Martin Zweifel, S. Riniker, W Schoenfeld, Patrik Weder, Martin Bigler, Cristiana Sessa, R. von Moos, Olivia Pagani
Publikováno v:
Cancer Research. 76:P5-14
Background: CR1447 (4-OH-testosterone, 4-OHT), a steroidal small molecule, strongly binds to the androgen receptor (AR) and has aromatase inhibiting activity. Pre-clinical studies show that CR1447 given as an ointment is efficiently absorbed and has
Autor:
Fabrizio Fasolini, Karin Ribi, Walter R. Marti, Nicolas Demartines, Gaudenz Curti, Bruno Lerf, Stefanie Hayoz, Martin Bigler, Markus Zuber, Beat Gloor, Christoph Kettelhack, Heinz Wehrli, Christiane Andrieu, Christian T. Hamel, Felix Grieder, Michael Graf
Publikováno v:
Marti, Walter R; Curti, Gaudenz; Wehrli, Heinz; Grieder, Felix; Graf, Michael; Gloor, Beat; Zuber, Markus; Demartines, Nicolas; Fasolini, Fabrizio; Lerf, Bruno; Kettelhack, Christoph; Andrieu, Christiane; Bigler, Martin; Hayoz, Stefanie; Ribi, Karin; Hamel, Christian (2019). Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision: A Swiss Prospective, Randomized, Multicenter Trial (SAKK 40/04). Annals of surgery, 269(5), pp. 827-835. Lippincott Williams & Wilkins 10.1097/SLA.0000000000003057
OBJECTIVE To compare, in a phase 3, prospective, randomized, multi-center clinical trial functional outcome of reconstruction procedures following total mesorectal excision (TME). SUMMARY BACKGROUND DATA Intestinal continuity reconstruction following
Autor:
Beatrice, Drexler, Jakob R, Passweg, Alexandar, Tzankov, Martin, Bigler, Alexandre Pa, Theocharides, Nathan, Cantoni, Peter, Keller, Georg, Stussi, Axel, Ruefer, Rudolf, Benz, Geneviève, Favre, Pontus, Lundberg, Ronny, Nienhold, Andrea, Fuhrer, Christine, Biaggi, Markus G, Manz, Mario, Bargetzi, Simon, Mendez-Ferrer, Radek C, Skoda
Publikováno v:
Haematologica
The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tes
Autor:
Matthias Schwenkglenks, Daniela Bertschi, Jörg Brechbühl, Klazien Matter-Walstra, U Hasler-Strub, Christoph Rochlitz, Martin Bigler, Andreas Müller, Ralph Winterhalder, Roger von Moos
Publikováno v:
Cancer Research. 75:P1-10
Background: Bevacizumab combined with chemotherapy has been shown to improve response rate and progression free survival in metastatic breast cancer. The aim of the health economic analysis (HEA) of this study was to demonstrate that the combination